Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.79 |
| ▸ | PGR | P06401 | 5/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291218 | 0.88 | NR3C1 (0.75) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL300222 | 0.86 | NR3C1 (0.65) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL6384755 | 0.84 | NR3C1 (1.00) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL5801885 | 0.84 | NR3C1 (1.00) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL6384458 | 0.83 | NR3C1 (0.81) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL5799890 | 0.82 | NR3C1 (0.82) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL291699 | 0.82 | NR3C1 (0.82) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL15756226 | 0.82 | NR3C1 (1.00) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL291131 | 0.82 | NR3C1 (0.75) | NR3C1CYP3A4PGRKCNH2NR3C2 | |
| SCHEMBL6387357 | 0.81 | NR3C1 (1.00) | NR3C1CYP3A4PGRKCNH2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | claimed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741897-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | SOLTA MEDICAL, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.) | 2011-05-05 | — | — | US | disclosed |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | BAUSCH & LOMB INCORPORATED | 2008-03-13 | — | — | US | disclosed |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | VRX HOLDCO LLC | 2008-03-06 | — | — | US | disclosed |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | BAUSCH HEALTH COMPANIES INC. (CA) | 2008-02-07 | — | — | US | disclosed |
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176706-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885CYP3A4 435/4885PGR 95/4885 |
| US-20080033008-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFECTIONS AND SEQUELAE THEREOF | NR3C1, GNRHR, GSR | NR3C1 1/4885CYP3A4 802/4885PGR 39/4885 |
| US-20110105559-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885CYP3A4 1344/4885PGR 123/4885 |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | PTGIR, PTGDR, NR3C1 | NR3C1 3/4885CYP3A4 1363/4885PGR 195/4885 |
| US-20120065228-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING OCULAR INFLAMMATORY WITH LOWER RISK OF INCREASED INTRAOCULAR PRESSURE | PTGIR, NR3C1, PTGDR | NR3C1 2/4885CYP3A4 1450/4885PGR 272/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C1 3/4885CYP3A4 831/4885PGR 220/4885 |
| US-20080064721-A1 | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy | CYSLTR1, LTB4R, CYSLTR2 | NR3C1 18/4885CYP3A4 1344/4885PGR 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.